Surv BioPharma Announces License Agreement with Nippon Zoki Pharmaceutical for Oncolytic Virus "Surv.m-CRA-1"
Surv BioPharma Inc. and Nippon Zoki Pharmaceutical Co., Ltd. have entered into a license agreement for the oncolytic virus “Surv.m-CRA-1” for the treatment of bone and soft tissue tumors.
For more details regarding this agreement, please refer to the link below.